반응식
[CH2:1]([O:5][C:6]1[CH:7]=[CH:8][C:9]([C:12]([OH:14])=O)=[N:10][CH:11]=1)[C:2]#[C:3][CH3:4].[CH3:15][C:16]1[C:17]([NH2:31])=[N:18][C:19]2([C:29]3[C:24](=[CH:25][CH:26]=[C:27]([NH2:30])[CH:28]=3)[O:23][CH2:22][CH2:21]2)[N:20]=1>>[NH2:31][C:17]1[C:16]([CH3:15])=[N:20][C:19]2([C:29]3[C:24](=[CH:25][CH:26]=[C:27]([NH:30][C:12](=[O:14])[C:9]4[CH:8]=[CH:7][C:6]([O:5][CH2:1][C:2]#[C:3][CH3:4])=[CH:11][N:10]=4)[CH:28]=3)[O:23][CH2:22][CH2:21]2)[N:18]=1참가 물질
3
실험 절차
The title compound (15 mg, 16% yield) was prepared as described for Example 13a starting from 5-(but-2-ynyloxy)picolinic acid (Intermediate 19, 45 mg, 0.24 mmol) and 5′-methylspiro[chroman-4,2′-imidazole]-4′,6-diamine (Intermediate 30, 54.7 mg, 0.24 mmol): 1H NMR (500 MHz, CDCl3) δ ppm 1.87 (t, 3 H), 2.03 (m, 1 H), 2.30 (m, 1 H), 2.39 (m, 3 H), 4.50 (m, 1 H), 4.62 (m, 1 H), 4.76 (m, 2 H), 6.92 (d, 1 H), 6.98 (m, 1 H), 7.41 (dd, 1 H), 7.49 (m, 1 H), 8.18 (d, 1 H), 8.28 (d, 1 H), 9.61 (s, 1 H); MS (ES+) m/z 404 [M+H]+.
출처 및 근거
- ORD 기록
- ord-a2d683ababbf47a282ae3fce9ea9156d
- 출처 데이터셋
- uspto-grants-2014_10
- 특허 번호
- US08865911B2
연결된 노트
불러오는 중…